Hepatology · Article 189

How Is Hepatitis D Treated in 2026?

Hepatitis D treatment requires a structured, evidence-based clinical approach. This review summarizes the key diagnostic, management, monitoring and decision points for gastroenterology and hepatology practice.

Hepatitis D treatment clinical reference — Related free clinical resource: Guideline-Based Management in Hepatology.

Hepatitis D treatment: practical clinical approach

This page focuses on Hepatitis D treatment with emphasis on decisions that change patient care, common pitfalls, and the current evidence base.

External guidance for Hepatitis D treatment

Clinical takeaway: For Hepatitis D treatment, decisions should integrate current guidelines, patient-specific risk, and the evidence summarized below.

Answer first: In May 2026, the FDA approved bulevirtide-gmod (Hepcludex) as the first U.S.-approved treatment for chronic HDV in adults without cirrhosis or with compensated cirrhosis. It is administered subcutaneously and reduces HDV RNA and ALT; optimal treatment duration remains uncertain. Underlying HBV should still be managed appropriately with a nucleos(t)ide analogue when indicated, but HBV antivirals alone do not suppress HDV RNA. Pegylated interferon remains an option in selected patients, especially where bulevirtide is unavailable, but tolerability and contraindications limit use.

Bulevirtide changes the treatment landscape

It blocks viral entry through NTCP and has demonstrated increasing virologic response with longer treatment.

Compensated versus decompensated disease matters

The current U.S. indication is adults without cirrhosis or with compensated cirrhosis.

HBV still requires separate management

Tenofovir or entecavir controls HBV replication but does not directly treat HDV.

Practical clinical algorithm

1. Confirm active chronic HDV with HDV RNA.

2. Stage cirrhosis and determine compensation status.

3. Consider bulevirtide in eligible adults according to local approval/label.

4. Treat underlying HBV when indicated.

5. Use pegylated interferon selectively when appropriate.

6. Monitor HDV RNA, ALT and hepatic function; monitor closely if therapy is discontinued.

Common mistakes to avoid

Treating HDV with tenofovir alone.
Using interferon in decompensated cirrhosis.
Assuming bulevirtide is a finite 12-week therapy.
Stopping bulevirtide without post-treatment monitoring.
Forgetting HCC surveillance.

Trainee takeaway

2026 is a major turning point for HDV: clinicians now have a dedicated antiviral option rather than relying solely on interferon.

Frequently asked questions

Is bulevirtide FDA approved?

Yes, since May 22, 2026.

Does it cure HDV?

It can markedly suppress HDV RNA, but optimal duration and long-term cure rates remain under study.

Does tenofovir treat HDV?

No, though it may be needed to control the underlying HBV.

References

1. Thomson ABR. Clinical Pharmacology, Physiology and Pathophysiology: Gastroenterology, Hepatology, and Pancreaticobiliary Disorders. CAPstone Academic Publishers; 2024.

2. Thomson ABR. Guideline-Based Management in Hepatology. CAPstone Academic Publishers; 2015.

3. U.S. Food and Drug Administration. FDA Approves First Treatment for Chronic Hepatitis Delta Virus Infection. May 22, 2026.

4. Wedemeyer H, et al. A Phase 3 Randomized Trial of Bulevirtide in Chronic Hepatitis D. N Engl J Med. 2023.

Educational content only. Clinical decisions should incorporate the individual patient, local resources, product labeling, and the most current applicable guideline or regulatory information.

← Back to Clinical Questions